Propanc Biopharma (PPCB) AI Stock Analysis

• Market Cap: $3.33M
• Dividend Yield: N/A
• Average Volume (3M): 400.33K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.87
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 15,859,280
• 10 Day Avg. Volume: 553,394
• 30 Day Avg. Volume: 400,327
• PEG Ratio: <0.01
• Price to Book (P/B): 1.18
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -40.64
• Enterprise Value/Market Cap: 1.21
• Enterprise Value/Revenue: 134.25
• Enterprise Value/Gross Profit: 30.41K
• Enterprise Value/Ebitda: -0.06
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: $0.21 ▼(-5.91% Downside)
• Action: N/A Date: 02/19/26
• Date: Action: N/A 02/19/26

The score is driven primarily by very weak financial performance (minimal revenue, large losses, and ongoing cash burn) and bearish technicals (price below major moving averages with negative MACD). Valuation offers little support due to losses and no dividend yield, while the Nasdaq bid-price compliance notice adds meaningful listing and financing risk.

Positive Factors

Patent/IP momentum

Filing multiple provisional patents materially strengthens the firm’s intellectual property estate, creating durable barriers to entry, improving licensing and partnership leverage, and protecting proprietary proenzyme formulations across jurisdictions as clinical development advances.

Advancing to Phase 1b

Transitioning from preclinical to a planned Phase 1b First‑In‑Human study is a structural de‑risking event: clinical progress validates development pathway, unlocks regulatory milestones, and materially increases the company's ability to form strategic alliances and access non-dilutive or milestone-based funding.

Low financial leverage

Very low debt leaves the company with financial flexibility to prioritize R&D and trials without heavy interest burdens. Improved equity reduces immediate solvency risk and supports negotiating partnerships or staged financings while clinical programs progress.

Negative Factors

Persistent cash burn

Sustained negative operating and free cash flow means the company cannot self‑fund development. Continued burn requires regular external financing, increasing dilution risk and potentially forcing unfavorable financing terms that can impair long‑term shareholder value.

Minimal, inconsistent revenue

Effectively pre‑commercial operations with near‑zero revenue indicate the business is not generating scale income. This extends time to sustainable profitability, increases reliance on capital markets, and raises execution risk for converting clinical progress into recurring sales.

Nasdaq listing risk

A minimum bid price deficiency creates a tangible delisting threat. Loss of Nasdaq listing would reduce liquidity, hinder future capital raising, limit access to public markets and equity incentives, and materially constrain the company’s ability to finance lengthy clinical development.

Propanc Biopharma Business Overview & Revenue Model

Company Description

Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

How the Company Makes Money

Propanc Biopharma Financial Statement Overview

Summary

Income statement is extremely weak with minimal TTM revenue (~$0.03M) and very large operating/net losses; cash flow remains negative with continued burn (~-$3.1M TTM operating cash flow and free cash flow). Balance sheet shows low leverage (debt-to-equity ~0.01) and a recent swing to positive equity, but returns remain very negative, indicating ongoing value erosion and funding dependence.

Income Statement

TTM (Trailing-Twelve-Months) shows only ~$0.03M of revenue with a modest gross margin (~21%), but profitability is extremely weak with very large operating and net losses (net margin deeply negative). Annual results historically show no revenue for multiple years, suggesting the business remains pre-commercial and dependent on funding rather than operating scale. Strength: some gross profit in TTM; Weakness: losses are overwhelmingly disproportionate to revenue and have recently expanded materially.

Balance Sheet

Leverage appears low in TTM with minimal debt relative to equity (debt-to-equity ~0.01), which is a positive for financial flexibility. However, returns remain very negative (TTM return on equity around -6), indicating ongoing value erosion. The balance sheet also shows prior periods with negative equity (2021–2024), followed by a sharp swing to positive equity in 2025 annual data—an improvement, but also a sign the capital structure may have changed materially and could be less stable/recurring than operating performance.

Cash Flow

Cash generation is weak: TTM operating cash flow and free cash flow are both negative (~-$3.1M), reflecting continued cash burn. While free cash flow growth is shown as improving, the company still does not fund operations internally, and cash outflows are large relative to the current revenue base. Strength: cash burn appears to have improved versus some prior periods; Weakness: still consistently negative cash flow with no clear self-sustaining operating cash profile.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	29.90K	0.00	0.00	0.00	0.00	0.00
Gross Profit	132.00	0.00	-21.66K	-17.76K	-5.67K	0.00
EBITDA	-62.93M	-58.34M	-1.26M	-2.23M	-2.14M	-1.69M
Net Income	-66.07M	-58.92M	-1.82M	-2.66M	-2.66M	-2.03M
Balance Sheet
Total Assets	15.11M	19.63M	72.36K	60.33K	81.65K	13.10K
Cash, Cash Equivalents and Short-Term Investments	561.24K	12.09K	21.09K	10.05K	4.07K	2.25K
Total Debt	1.68M	1.73M	948.27K	545.92K	1.04M	680.08K
Total Liabilities	4.66M	5.73M	3.85M	3.18M	3.11M	3.08M
Stockholders Equity	10.45M	13.91M	-3.78M	-3.12M	-3.02M	-3.07M
Cash Flow
Free Cash Flow	-3.10M	-405.17K	-935.12K	-1.11M	-1.44M	-1.15M
Operating Cash Flow	-3.10M	-405.17K	-935.12K	-1.11M	-1.44M	-1.15M
Investing Cash Flow	-4.76K	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	3.69M	490.76K	941.89K	1.11M	1.49M	1.06M

Propanc Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VRCA	56 Neutral	$97.06M	-1.83	―	―	234.73%	81.16%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BRNS	44 Neutral	$26.95M	-0.31	-62.30%	―	-100.00%	-26.30%
PPCB	39 Underperform	$3.33M	-0.01	-1163.67%	―	―	―

Propanc Biopharma Corporate Events

Propanc Biopharma Receives Nasdaq Minimum Bid Price Notice

On December 31, 2025, Propanc Biopharma received a notice from Nasdaq that its common stock no longer met the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market, after trading below that threshold for 35 consecutive business days. The company has until June 30, 2026, to regain compliance—either by its share price closing at or above $1.00 for at least ten consecutive business days or, if eligible, by using an additional 180-day compliance period that could include a reverse stock split—while its stock remains listed for now and business operations and SEC reporting are not immediately affected; however, potential delisting could reduce liquidity, hinder capital-raising efforts, limit access to public markets, and weaken its ability to offer equity incentives, posing significant risks to shareholders and corporate financing.